Skip to content
  • Argentina
  • Brazil
  • Canada
  • Chile
  • Colombia
  • Europe
  • France
  • Germany
  • India
  • Italy
  • Japan
  • Korea
  • Mexico
  • Perú
  • Russia
  • Spain
  • Taiwan
  • The Middle East
  • Turkey
  • United Kingdom
  • United States
  • Vietnam
  • Italia
    • Utenti registrati
    • 0039 0424-472449 Richiedi informazioni
    • 0039 0424-472449 Richiedi informazioni
    ItalyItaly
      • Part of brands: |
        • Guida
          • Prevenzione di malattie ereditarie
          • Gravidanza serena
        • I nostri servizi
          • Per gli specialisti della salute
          • Per i pazienti
        • Diagnostica
        • Chi Siamo
          • Igenomix Research
          • Chi siamo
        • Webinars
        Genomics Precision Diagnostic > Oncology > Lung Cancer Precision Panel

        Lung Cancer

        Lung cancer is the leading cause of cancer death worldwide, with 90% of cases being attributable to smoking. It is the second most common cancer, and it is a malignancy that affects either the lung tissue or the airways.
        Overview
        Indication
        Clinical Utility
        Genes & Diseases
        Methodology
        References

        Overview

        • Lung cancer is the leading cause of cancer death worldwide, with 90% of cases being attributable to smoking. It is the second most common cancer, and it is a malignancy that affects either the lung tissue or the airways. Risk factors for lung cancer include cigarette smoking, asbestos, radon and family history of lung cancer. Lung cancer can be sporadic or associated to a hereditary cancer syndrome.
        • Hereditary cancer syndromes are encountered in all medical specialties. Although they account for about 5% of all malignancies, it is of special importance to identify these patients because, unlike patients with sporadic cancers, they require special, long-term care as their predisposition can cause them to develop certain tumors at a relatively early age. Most hereditary cancers are associated with a “germline mutation” that will be present in every cell of the human body. Identification of patients at risk of inherited cancer susceptibility is dependent upon the ability to characterize genes and alterations associated with increased cancer risk as well as gathering a detailed personal and family history aiding in the identification of the mode of inheritance as well as other family members at risk of suffering from this susceptibility. Most hereditary cancer syndromes follow an autosomal dominant inheritance, and the penetrance is high.
        • The Igenomix Lung Cancer Precision Panel provides a comprehensive analysis of the most common genes responsible for the development of a malignant growth in the airways or lung tissue using next-generation sequencing (NGS) to fully understand the spectrum of relevant lung cancer predisposition genes.

        Indication

        The Igenomix Lung Cancer Precision Panel is indicated as a screening and diagnostic test in those cases where there is:

        • Cough
        • Wheezing
        • Unintentional weight loss
        • Hemoptysis
        • Chest pain
        • Dyspnea
        • Horaseness
        • Family history of lung cancer

        Clinical Utility

        The clinical utility of this panel is: 

        • The genetic and molecular diagnosis for an accurate clinical diagnosis of a patient with personal or family history suggestive of a hereditary cancer syndrome with predisposition to lung cancer.
        • Early initiation of treatment with a multidisciplinary team for appropriate total body screening, early surgical intervention, or pharmacologic treatment. 
        • Risk assessment and genetic counselling of asymptomatic family members according to the mode of inheritance
        • Reduce morbidity related to lung cancer, or morbidity secondary to complications of surveillance and treatment.
        • Categorization of genetic alterations into predictive levels of standard, investigational or hypothetic target therapies in the molecular pathology reports.
        • Improved pathways from diagnosis to treatment in susceptible populations.

        Genes & Diseases

        Methodology

        References

        See scientific referrals

        Parikh A. R. (2019). Lung Cancer Genomics. Acta medica academica, 48(1), 78–83. https://doi.org/10.5644/ama2006-124.244

        National Comprehensive Cancer Network.  (2021). Retrieved from https://www.nccn.org/professionals/physician_gls/default.aspx#detection

        Lara-Guerra, H., & Roth, J. A. (2016). Gene Therapy for Lung Cancer. Critical reviews in oncogenesis, 21(1-2), 115–124. https://doi.org/10.1615/CritRevOncog.2016016084

        Tímár, J., Méhes, G., & Vass, L. (2020). A tüdőrák molekuláris diagnosztikájának modern szemlélete és klinikai jelentősége [Molecular diagnostics of lung cancer and its clinical relevance]. Magyar onkologia, 64(3), 183–189.

        Nishimura, T., Nakamura, H., Végvári, Á., Marko-Varga, G., Furuya, N., & Saji, H. (2019). Current status of clinical proteogenomics in lung cancer. Expert review of proteomics, 16(9), 761–772. https://doi.org/10.1080/14789450.2019.1654861

        descargar

        Detail description

        Download

        BROCHURE

        Download

        Request Information


        • reCAPTCHA demo: Simple page

        GUIDA

        Fertilità
        Prevenzione di malattie ereditarie
        Gravidanza serena

        I NOSTRI SERVIZI

        Soluzioni genetiche
        Informazioni sulla genetica

        PANORAMICA

        Informazioni su Igenomix
        Contatti
        Come inviare un campione
        Qualità
        Lavora con noi
        News and Press

           0039 0424-472449
        Contatti
        • Argentina
        • Brazil
        • Canada
        • Chile
        • Colombia
        • Europe
        • France
        • Germany
        • India
        • Italy
        • Japan
        • Korea
        • Mexico
        • Perú
        • Russia
        • Spain
        • Taiwan
        • The Middle East
        • Turkey
        • United Kingdom
        • United States
        • Vietnam
        Linguaggio

        [2019] © Igenomix Politica sulla privacyPolitica qualità Politica dei cookie       Soddisfazione       Manuale dell’utente

        Richiedi informazioni








        • reCAPTCHA demo: Simple page











        • Guida
          • Prevenzione di malattie ereditarie
          • Gravidanza serena
        • I nostri servizi
          • Per gli specialisti della salute
          • Per i pazienti
        • Diagnostica
        • Chi Siamo
          • Igenomix Research
          • Chi siamo
        • Webinars
        • Italia
        • Utenti registrati
        • Area pazienti
        • Area cliniche

        We are using cookies to give you the best experience on our website.

        You can find out more about which cookies we are using or switch them off in settings.

        Italy
        Powered by  GDPR Cookie Compliance
        Privacy Overview

        This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

        Strictly Necessary Cookies

        Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

        If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.